<?xml version="1.0" encoding="UTF-8"?>
<p>Most of these medicinal products will have to be managed in a hospital setting, which is why the interdisciplinary pharmacotherapy committees need to consider all levels of evidence generated, focusing specifically on data related to clinical safety and efficacy comparability. The establishment of equivalence of clinical safety and efficacy for medicinal products classified as NBCDs needs the provision of adequate clinical data [(
 <xref rid="B27" ref-type="bibr">27</xref>); see also (
 <xref rid="B28" ref-type="bibr">28</xref>)].
</p>
